Summary of COVID-19 asapiprant studies

1. Wilkerson et al., A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy and Safety of BGE-175 in Hospitalized Adults With COVID-19

194 patient asapiprant late treatment RCT: 63% higher mortality (p=0.21), 32% higher ICU admission (p=0.37), 24% higher severe cases (p=0.36), and 33% slower improvement (p=0.17).
RCT 194 hospitalized COVID-19 patients showing no significant differences with asapiprant (BGE-175).
May 2022, NCT04705597, https://clinicaltrials.gov/study/NCT04705597, https://c19p.org/wilkerson